| 1.33 0.01 (0.76%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.7 | 1-year : | 1.91 |
| Resists | First : | 1.45 | Second : | 1.63 |
| Pivot price | 1.27 |
|||
| Supports | First : | 1.15 | Second : | 0.96 |
| MAs | MA(5) : | 1.31 |
MA(20) : | 1.3  |
| MA(100) : | 1.63 |
MA(250) : | 2.11 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 48.5 |
D(3) : | 42.3 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 4.55 | Low : | 1.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRDF ] has closed below upper band by 16.6%. Bollinger Bands are 60.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.34 |
| Low: | 1.23 - 1.23 | 1.23 - 1.24 |
| Close: | 1.32 - 1.33 | 1.33 - 1.34 |
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Wed, 08 Jul 2026
Cardiff Oncology (CRDF) Noble Capital Markets Emerging Growth Virtual Investor Conference summary - Quartr
Tue, 07 Jul 2026
Price to earnings forward of Cardiff Oncology, Inc. – NASDAQ:CRDF - TradingView
Tue, 30 Jun 2026
Is Cardiff Oncology, Inc. (CRDF) Stock Undervalued Amid Legal Uncertainty and Future Cancer Drug Potential? - Yahoo Finance
Mon, 22 Jun 2026
Insider Buying: Mani Mohindru Acquires Shares of Cardiff Oncology Inc (CRDF) - GuruFocus
Mon, 22 Jun 2026
Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market - Stock Titan
Mon, 22 Jun 2026
Cardiff Oncology (CRDF) CEO makes open-market buy of 24,703 shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 6.669e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 18,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.707e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -31 % |
| Return on Assets (ttm) | 341.4 % |
| Return on Equity (ttm) | -44.3 % |
| Qtrly Rev. Growth | 525000 % |
| Gross Profit (p.s.) | -45.22 |
| Sales Per Share | -61.45 |
| EBITDA (p.s.) | -2.2529e+007 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 3.59 |
| Dividend | 0 |
| Forward Dividend | 1.615e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|